Skip to main content
Clinical Trials/NCT01710020
NCT01710020
Completed
Phase 1

Phase 1, Open-Label Study Of The Pharmacokinetics, Non-Renal Clearance And Dialyzability Of CP-690,550 In Subjects With End-Stage Renal Disease Undergoing Hemodialysis

Pfizer1 site in 1 country12 target enrollmentFebruary 2003

Overview

Phase
Phase 1
Intervention
CP-690,550
Conditions
End-Stage Renal Disease
Sponsor
Pfizer
Enrollment
12
Locations
1
Primary Endpoint
Maximum Observed Plasma Concentration (Cmax)
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

There were 2 study periods in this study. In the Period 1, CP-690,550 was to be administered approximately 1 to 2 hours following hemodialysis. If significant non-renal clearance of the drug occurred such that dialyzability of CP-690,550 could not be assessed in Period 1, a second period (Period 2) will be conducted. In Period 2, a single dose of drug will be administered approximately 4 hours prior to hemodialysis.

Registry
clinicaltrials.gov
Start Date
February 2003
End Date
June 2003
Last Updated
13 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Pfizer
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects with end-stage renal disease
  • Subjects need hemodialysis 3 times weekly

Exclusion Criteria

  • Subjects with evidence or history of clinically significant disease, excluding those common for subjects with End-Stage Renal Disease (ESRD).
  • Subjects with any condition possibly affecting drug absorption.
  • Subjects with malignancies with the exception of adequately treated basal cell carcinoma of the skin.

Arms & Interventions

CP-690,550

Intervention: CP-690,550

Outcomes

Primary Outcomes

Maximum Observed Plasma Concentration (Cmax)

Time Frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1

Time to Reach Maximum Observed Plasma Concentration (Tmax)

Time Frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1

Plasma Decay Half-Life (t1/2)

Time Frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

Time Frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hours (hrs) post-dose in Period 1

AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

Time Frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

Oral Clearance (CLpo)

Time Frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. It was calculated by dividing given dose of drug with AUC.

Dialyser Clearance (CL HD) From 0 to 1 Hour

Time Frame: 0 to 1 hrs during hemodialysis started 4 hrs post-dose in Period 2

Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided (/) by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).

Dialyser Clearance (CL HD) From 1 to 2 Hour

Time Frame: 1 to 2 hrs during hemodialysis started 4 hrs post-dose in Period 2

Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).

Dialyser Clearance (CL HD) From 2 to 3 Hour

Time Frame: 2 to 3 hrs during hemodialysis started 4 hrs post-dose in Period 2

Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).

Dialyser Clearance (CL HD) From 3 to 4 Hour

Time Frame: 3 to 4 hrs during hemodialysis started 4 hrs post-dose in Period 2

Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).

Secondary Outcomes

  • Fraction of Unbound Drug (fu)(2 hours post-dose in Period 1)

Study Sites (1)

Loading locations...

Similar Trials